Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (737)	9/12/2003 3:59:00 AM
From: Icebrg	Read Replies (1) \| Respond to of 2240

The Second Journees des Cordeliers: Latest Advances in Immunotherapy Against Cancer Friday September 12, 2:00 am ET PARIS--(BUSINESS WIRE)--Sept. 12, 2003--Immunotherapy and its applications in cancer will be the focus of the second Journees des Cordeliers in Paris from October 1-3, 2003. This international scientific event is organized by Universite Pierre et Marie Curie (UPMC) and the biopharmaceutical firm, IDM (Immuno-Designed Molecules), one of the European leaders in immunotherapy against cancer. It will be presided by Professor Herve Fridman, director of the Immunotherapy Department at Hopital Europeen Georges Pompidou (Paris) and president of the IDM Scientific Board. The Second Journees des Cordeliers will assess tumour and its micro-environment, as well as future therapeutic approaches. This congress will provide an opportunity to present and discuss the results of clinical trials on immunotherapy products derived from biotechnologies designed to fight cancer. Almost 150 researchers and clinicians from three continents will attend this congress. About twenty internationally known experts will present their work and the advances made in the treatment of cancers, including basic and applied immunology. Among them, Professor Michael Fanger (Dartmouth Medical School) and Professor Pierre Coulie (Universite de Louvain) will discuss therapeutic vaccines, Professor Michael Lotze (Pittsburg Cancer Institute) will discuss serum proteomic markers, and Professor Reinhard Andreesen (Regensburg University, Germany) will discuss tumor antigen specific T-Cells. The Journees des Cordeliers bears the name of the UPMC Cordeliers Research Center and is the result of a successful alliance between the worlds of academics and applied research, universities and biotechnology companies. UPMC Cordeliers Research Center has set a standard for excellence in immunology research, and has an active policy of technology transfer. Its collaboration with IDM, which set up one of its research laboratories at Institut des Cordeliers, is a fine example of the collaboration between the public and private sectors. Their continuous and intense exchange of data helps optimise research parameters and accelerates the evaluation of new treatments against cancer, a disease that kills 56 million people throughout the world each year. IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system, destroy residual tumor cells, and immunize patients to prevent tumor recurrence. IDM's most advanced product is in Phase III for the treatment of ovarian cancer.